Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
Axogen (NASDAQ: AXGN), a leader in peripheral nerve function restoration solutions, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will be conducting one-on-one meetings with investors on Tuesday, August 12, 2025.
Axogen (NASDAQ: AXGN), azienda leader nelle soluzioni per il ripristino della funzione dei nervi periferici, ha annunciato la sua partecipazione al Canaccord Genuity 45° Annual Growth Conference. Il team di gestione della società terrà incontri individuali con gli investitori il martedì 12 agosto 2025.
Axogen (NASDAQ: AXGN), líder en soluciones para la restauración de la función de nervios periféricos, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo directivo de la compañía realizará reuniones individuales con inversores el martes 12 de agosto de 2025.
Axogen (NASDAQ: AXGN)은 말초 신경 기능 회복 솔루션 분야의 선도 기업으로, Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 8월 12일 화요일에 투자자들과 일대일 미팅을 진행할 예정입니다.
Axogen (NASDAQ : AXGN), leader dans les solutions de restauration de la fonction nerveuse périphérique, a annoncé sa participation à la 45e conférence annuelle de croissance Canaccord Genuity. L'équipe de direction de la société tiendra des réunions individuelles avec les investisseurs le mardi 12 août 2025.
Axogen (NASDAQ: AXGN), ein führendes Unternehmen für Lösungen zur Wiederherstellung der peripheren Nervenfunktion, hat seine Teilnahme an der Canaccord Genuity 45. jährlichen Wachstumskonferenz angekündigt. Das Management-Team des Unternehmens wird am Dienstag, den 12. August 2025, Einzelgespräche mit Investoren führen.
- None.
- None.
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products used across various applications and surgical specialties, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and the surgical treatment of pain. These applications encompass both scheduled and emergent procedures. Specifically, scheduled procedures are often pursued by patients seeking relief from conditions caused by a nerve defect or previous surgical interventions. Such procedures include providing sensation for women undergoing breast reconstruction following a mastectomy, nerve reconstruction after the surgical removal of painful neuromas, and oral and maxillofacial procedures, as well as nerve decompression. Conversely, emergent procedures typically arise from injuries that initially present in an emergency room, with specialists intervening either immediately or within a few days following the initial injury. This broad range of applications underscores Axogen’s vital role in addressing diverse patient needs in peripheral nerve repair. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft®, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international markets.
For more information, visit www.axogeninc.com
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
FAQ
When is Axogen (AXGN) presenting at the Canaccord Genuity Growth Conference?
What type of company is Axogen (AXGN)?
What is the format of Axogen's participation at the Canaccord conference?
Which conference is Axogen (AXGN) attending in August 2025?
